TD Cowen raised the firm’s price target on Ultragenyx to $61 from $59 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 earnings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx initiated with an Outperform at RBC Capital
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 4/17/2024, According to Top Analysts
- Ultragenyx announces results from interim Phase 1/2 data of GTX-102
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome